Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) was the recipient of a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 316,600 shares, a drop of 30.7% from the October 31st total of 457,100 shares. Currently, 7.8% of the shares of the company are sold short. Based on an average trading volume of 2,780,000 shares, the days-to-cover ratio is presently 0.1 days.
Analyst Ratings Changes
Separately, Benchmark reiterated a “buy” rating and set a $7.00 price target on shares of Biofrontera in a research report on Friday, November 15th.
Biofrontera Price Performance
About Biofrontera
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
Read More
- Five stocks we like better than Biofrontera
- How to Invest in Insurance Companies: A GuideĀ
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- EV Stocks and How to Profit from Them
- 3 Penny Stocks Ready to Break Out in 2025
- What is MarketRankā¢? How to Use it
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.